Evidence map›Paper›PMID 41133677›Full record

ArticleAntibodies (Basel, Switzerland)2025

Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL.

Tristan Mangeat, Célestine Mairaville, Myriam Chentouf, Madeline Neiveyans, Martine Pugnière, Giang Ngo, Vincent Denis, Corentin Catherine, Alexandre Pichard, Emmanuel Deshayes and 8 more

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tristan MangeatInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0009-0003-0000-6218
Célestine MairavilleInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0000-0001-6867-3357
Myriam ChentoufInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.
Madeline NeiveyansInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0009-0001-6609-8616
Martine PugnièreInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0000-0002-2049-2909
Giang NgoInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.
Vincent DenisInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.
Corentin CatherineInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.
Alexandre PichardInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.
Emmanuel DeshayesInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0000-0002-8408-4947
Margaux MaurelInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0009-0007-0569-6085
Matthieu GraciaInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0009-0006-9960-8156
Anne BigotInstitut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, 75013 Paris, France.
Vincent MoulyInstitut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, 75013 Paris, France.
Sébastien EstaranInstitut des Biomolécules Max Mousseron, Université Montpellier, Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), 34090 Montpellier, France.
Alain ChavanieuInstitut des Biomolécules Max Mousseron, Université Montpellier, Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), 34090 Montpellier, France.ORCID 0000-0002-0512-5115
Pierre MartineauInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0000-0002-7993-7183
Bruno RobertInstitut de Recherche en Cancérologie de Montpellier (IRCM), Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), INSERM, 34298 Montpellier, France.ORCID 0000-0001-5573-6945

Funding

Agence Nationale de la Recherche ANR-10-LABX-53La Ligue Contre le Cancer StudenshipLigue Régionale Contre le Cancer de la Lozère R20031FF
6 · The paper itself

Abstract

BACKGROUND/

objectivesTumor-associated antigens are not tumor-specific antigens but proteins that are overexpressed by tumor cells and also weakly expressed at the surface of healthy tissues. Therefore, some side effects are observed when targeted by therapeutic antibodies, a phenomenon named "on-target, off-tumor toxicity". As tumors generate an acidic microenvironment, we investigated whether we could generate pH-dependent antibodies to increase their tumor specificity. For this proof-of-concept study, we selected the tyrosine kinase receptor AXL because we already developed several antibodies against this target.

methodsTo generate a pH-dependent anti-AXL antibody, we performed classical panning of a single-chain variable fragment (scFv) library using phage display at an acidic pH throughout the process.

resultsAfter the third round of panning, 9 scFvs, among the 96 picked clones, bound to AXL at acidic pH and showed very low binding at a neutral pH. After reformatting them into IgG, two clones were selected for further study due to their strong pH-sensitive binding. Using molecular docking and alanine scanning, we found that their binding strongly depended on two histidine residues present on AXL at positions 61 and 116.

conclusionsTo conclude, we set-up an easy process to generate pH-dependent antibodies that may increase their tumor-binding specificity and potentially decrease toxicity towards healthy tissues.

Indexed as

acidic pHAXLcancer immunotherapyphage displaypH dependent antibodiesWarburg effect

Identifiers

PMID41133677
PMCPMC12550914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.